Cdk6 degradation is counteracted by p16ink4a and p18ink4c in aml

HIGHLIGHTS

• who: Belinda S. Schmalzbauer et al. from the Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, Vienna, Austria have published the Article: CDK6 Degradation Is Counteracted by p16INK4A and p18INK4C in AML, in the Journal: Cancers 2022, 14, 1554. of 10/03/2022
• what: The authors show that the efficacy of the CDK6specific protein degrader BSJ-03-123 varies among subtypes and depends on the low expression of the proteins p16INK4A and p18INK4C protein levels are significantly elevated in KMT2A-MLLT3+ cells compared to RUNX1-RUNX1T1+ cells contributing to the different degradation efficacy . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.